Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions

This publication has 28 references indexed in Scilit:

• Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: The Memorial Sloan-Kettering Cancer Center experience
  Gynecologic Oncology, 2003
• Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
  International Journal of Gynecologic Cancer, 2003
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
  The Lancet, 2003
• International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma
  JNCI Journal of the National Cancer Institute, 2003
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
  The Lancet, 2002
• Hypersensitivity Reactions and the Utility of Oral and Intravenous Desensitization in Patients with Gynecologic Malignancies
  Gynecologic Oncology, 2001
• A new standard of care for treatment of ovarian cancer
  European Journal Of Cancer, 2000
• Clinical Features of Hypersensitivity Reactions to Carboplatin
  Journal of Clinical Oncology, 1999
• ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
  The Lancet, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996